Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

An agent is described that includes a plant virus particle or VLP conjugate to TRAIL. Associating TRAIL with the plant virus particle or VLP serves to both target cancer cells and induce their apoptosis. The agent can therefore be used for a method of treating cancer in a subject.

The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Step dosing of the anti-DLL3 agent for the treatment of SCLC is also disclosed.

Use of an agent capable of inhibiting CLEVER-1 expression or binding to CLEVER-1 in combination with an inhibitor of interleukin and/or the respective receptor, and optionally further with an agent capable of binding to interferon-alpha/beta receptor (IFNAR) in a treatment of diseases.

Use of an agent capable of inhibiting CLEVER-1 expression or binding to CLEVER-1 in combination with an inhibitor of interleukin and/or the respective receptor, and optionally further with an agent capable of binding to interferon-alpha/beta receptor (IFNAR) in a treatment of diseases.

The present invention provides a variety of methods for the identification and/or treatment of subjects that are at risk for developing life-threatening complications of SARS-CoV-2 infection and other infections. Such methods involve determining if a subject has clonal hematopoiesis.

In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.

Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.

Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.